decisionhealth Newsletters, Coder Pink Sheets - 2013 Issue 6 (June)
Follow these drug-billing tips to lower your J-code denial rate, reduce audit
Subscribe or sign in to view the full article.
Article Overview
This article is a practical Medicare drug-billing guidance piece for clinicians, coders, billing staff, and compliance teams. It explains the broad areas that can trigger denials or audit scrutiny in J-code billing, including drug wastage reporting, ownership of the drug expense, place-of-service considerations, dosage/unit reporting, and the use of selected modifiers. The discussion is framed around avoiding billing errors and improving claim accuracy.
Why This Topic Matters
Drug billing mistakes can lead to denials, repayments, and audit risk. This article helps readers understand the main documentation and claim-reporting areas to review when billing Medicare for drugs and biologicals.
What You Will Learn
- Key drug-billing areas that affect Medicare claims
- How wastage documentation is addressed at a high level
- Why place of service can change how drug claims are paid
- How dosage and units can affect J-code reporting
- Which common modifiers are discussed in the article
Who Should Read This
- Medical coders
- Billing staff
- Revenue cycle teams
- Compliance staff
- Physician practices
- Dialysis and infusion providers
Codes Discussed
Modifiers Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com